Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes

This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in patients with type 2 diabetes.

Inclusion Criteria:

• Diagnosis of type 2 diabetes
• Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels
• Outpatients

Exclusion Criteria:

• Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
• Significant cardiovascular complications as defined by the protocol
• Significant diabetic complications as defined by the protocol

Other protocol-defined inclusion/exclusion criteria may apply